And again... Keytruda challenger shapes up

In another impressive win, Akeso and Summit Therapeutics bispecific antibody ivonescimab reduced the risk of death for lung cancer patients by 27 per cent compared to MSD's Keytruda, updated data from the phase 3 HARMONi-2 trial has revealed.

To see the whole article please log in.

Simon Webster

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here